Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil

Mycoses

Volumn 61, Issue 1, 2018, Pages 11-21

  Canela, Heliara Maria Spina ^a   Cardoso, Bárbara ^a   Vitali, Lucia Helena ^a   Coelho, Harnoldo Colares ^a   Martinez, Roberto ^a   Ferreira, Márcia Eliana da Silva ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antifungal susceptibility; Candida spp.; candidemia; virulence factors

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; HEMOLYSIN; PHOSPHOLIPASE; PROTEINASE; VIRULENCE FACTOR; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BRAZIL; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FUNGAL VIRULENCE; FUNGUS ISOLATION; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY RATE; NEWBORN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SPECIES IDENTIFICATION; TERTIARY CARE CENTER; CLASSIFICATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOGENICITY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BRAZIL; CANDIDA; CANDIDA GLABRATA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; TERTIARY CARE CENTERS; VIRULENCE FACTORS; YOUNG ADULT;

EID: 85030168536     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12695     Document Type: Article

References (64)

1. Caggiano G, Coretti C, Bartolomeo N, et al. Candida bloodstream infections in Italy: changing epidemiology during 16 years of surveillance. Biomed Res Int. 2015;2015:256580.
2. da Costa VG, Quesada RM, Abe AT, Furlaneto-Maia L, Furlaneto MC. Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey. Mycopathologia. 2014;178:243-250.
3. De Rosa FG, Corcione S, Filippini C, et al. The effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. PLoS ONE. 2015;10:e0125149.
4. Marra AR, Camargo LF, Pignatari AC, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2563 cases from a prospective nationwide surveillance study. J Clin Microbiol. 2011;49:1866-1871.
5. Motta AL, Almeida GM, Almeida Júnior JN, Burattini MN, Rossi F. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis. 2010;14:441-448.
6. Bassetti M, Merelli M, Ansaldi F, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS ONE. 2015;10:e0127534.
7. Santos ER, Dal Forno CF, Hernandez MG, et al. Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. Rev Inst Med Trop Sao Paulo. 2014;56:477-482.
8. Colombo AL, Guimarães T, Silva LR, et al. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28:570-576.
9. Gong X, Luan T, Wu X, et al. Invasive candidiasis in intensive care units in China: risk factors and prognoses of Candida albicans and non-albicans Candida infections. Am J Infect Control. 2016;44:e59-e63.
10. Silva-Dias A, Miranda IM, Branco J, et al. Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: relationship among Candida spp. Front Microbiol. 2015;6:205.
11. Chan S, Baley ED, Hossain J, Di Pentima MC. Candida species bloodstream infections in hospitalized children: a 10-year experience. J Paediatr Child Health. 2015;51:857-860; quiz 861.
12. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5-10.
13. Fu J, Ding Y, Wei B, et al. Epidemiology of Candida albicans and non-C. albicans of neonatal candidemia at a tertiary care hospital in western China. BMC Infect Dis. 2017;17:329.
14. Mattei AS, Alves SH, Severo CB, et al. Determination of germ tube, phospholipase, and proteinase production by bloodstream isolates of Candida albicans. Rev Soc Bras Med Trop. 2013;46:340-342.
15. Chin VK, Foong KJ, Maha A, et al. Candida albicans isolates from a Malaysian hospital exhibit more potent phospholipase and haemolysin activities than non-albicans Candida isolates. Trop Biomed. 2013;30:654-662.
16. Tellapragada C, Eshwara VK, Johar R, et al. Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. J Pathog. 2014;2014:142864.
17. Martínez JM, Gómez EV, Pemán J, et al. Identification of pathogenic yeast species by polymerase chain reaction amplification of the RPS0 gene intron fragment. J Appl Microbiol. 2010;108:1917-1927.
18. Feng X, Wu Z, Ling B, et al. Identification and differentiation of Candida parapsilosis complex species by use of exon-primed intron-crossing PCR. J Clin Microbiol. 2014;52:1758-1761.
19. Mane A, Gaikwad S, Bembalkar S, Risbud A. Increased expression of virulence attributes in oral Candida albicans isolates from human immunodeficiency virus-positive individuals. J Med Microbiol. 2012;61(Pt 2):285-290.
20. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol. 2001;39:2971-2974.
21. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. (Approved standard. M27-A3).
22. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012 (Document M27-S4).
23. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol. 2011;49:630-637.
24. Clinical and Laboratory Standards Institute. Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 1st edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2016. (Document M59).
25. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol. 2011;49:3800-3804.
26. Wille MP, Guimarães T, Furtado GH, Colombo AL. Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil. Mem Inst Oswaldo Cruz. 2013;108:288-292.
27. Hoffmann-Santos HD, Paula CR, Yamamoto AC, Tadano T, Hahn RC. Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil. Mycopathologia. 2013;176:409-415.
28. Tan BH, Chakrabarti A, Li RY, et al. Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect. 2015;21:946-953.
29. Sutcu M, Salman N, Akturk H, et al. Epidemiologic and microbiologic evaluation of nosocomial infections associated with Candida spp in children: a multicenter study from Istanbul, Turkey. Am J Infect Control. 2016;44:1139-1143.
30. Vallabhaneni S, Mody RK, Walker T, Chiller T. The global burden of fungal diseases. Infect Dis Clin North Am. 2016;30:1-11.
31. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95-105.
32. Albataineh MT, Sutton DA, Fothergill AW, Wiederhold NP. Update from the laboratory: clinical identification and susceptibility testing of fungi and trends in antifungal resistance. Infect Dis Clin North Am. 2016;30:13-35.
33. Whibley N, Gaffen SL. Beyond Candida albicans: mechanisms of immunity to non-albicans Candida species. Cytokine. 2015;76:42-52.
34. Chen YC, Lin YH, Chen KW, et al. Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. Diagn Microbiol Infect Dis. 2010;68:284-292.
35. Ziccardi M, Souza LO, Gandra RM, et al. Candida parapsilosis (sensu lato) isolated from hospitals located in the Southeast of Brazil: species distribution, antifungal susceptibility and virulence attributes. Int J Med Microbiol. 2015;305:848-859.
36. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE. 2015;10:e0120452.
37. Chapman B, Slavin M, Marriott D, et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72:1103-1108.
38. Colombo AL, Garnica M, Aranha Camargo LF, et al. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol. 2013;51:38-44.
39. Pasqualotto AC, Zimerman RA, Alves SH, et al. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil. Infect Control Hosp Epidemiol. 2008;29:898-899.
40. Nucci M, Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ONE. 2013;8:e59373.
41. Siri L, Legarraga P, García P, González T, Rabagliati R. Clinical and epidemiological changes of candidemia among adult patients from 2000 to 2013. Rev Chilena Infectol. 2017;34:19-26.
42. Yeşilkaya A, Azap Ö, Aydın M, Akçil Ok M. Epidemiology, species distribution, clinical characteristics and mortality of candidaemia in a tertiary care university hospital in Turkey, 2007-2014. Mycoses. 2017;60:433-439.
43. Moretti ML, Trabasso P, Lyra L, et al. Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol. 2013;51:225-30.
44. Blanco-Blanco MT, Gómez-García AC, Hurtado C, et al. Candida orthopsilosis fungemias in a Spanish tertiary care hospital: incidence, epidemiology and antifungal susceptibility. Rev Iberoam Micol. 2014;31:145-148.
45. Taj-Aldeen SJ, Kolecka A, Boesten R, et al. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection. 2014;42:393-404.
46. McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin N Am. 2016;30:103-124.
47. Pemán J, Quindós G. Current aspects of invasive diseases caused by Candida and other yeast fungi. Rev Iberoam Micol. 2016;33:133-139. [in Spanish].
48. Gupta A, Varma A. Candida glabrata candidemia: an emerging threat in critically ill patients. Indian J Crit Care Med. 2015;19:151-154.
49. Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Microbiol Rep. 2015;2:84-95.
50. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(Suppl 2):2-13.
51. Fan X, Xiao M, Liao K, et al. Notable increasing trend in azole non-susceptible Candida tropicalis causing invasive Candidiasis in China (August 2009 to July 2014): molecular epidemiology and clinical azole consumption. Front Microbiol. 2017;8:464.
52. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging Non-albicans Candida species. Front Microbiol. 2016;7:2173.
53. Whaley SG, Tsao S, Weber S, Zhang Q, Barker KS, Raymond M, Rogers PD. The RTA3 Gene, Encoding a Putative Lipid Translocase, Influences the Susceptibility of Candida albicans to Fluconazole. Antimicrob Agents Chemother. 2016;60:6060-6066.
54. Rosana Y, Yasmon A, Lestari DC. Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia. J Med Microbiol. 2015;64:1046-1052.
55. Salari S, Khosravi AR, Mousavi SA, Nikbakht-Brojeni GH. Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis. J Mycol Med. 2016;26:35-41.
56. Zhang L, She X, Merenstein D, et al. Fluconazole resistance patterns in Candida species that colonize women with HIV infection. Curr Ther Res Clin Exp. 2014;76:84-89.
57. Abrantes PMS, McArthur CP, Africa CW. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon. Diagn Microbiol Infect Dis. 2014;79:222-227.
58. Paula SB, Morey AT, Santos JP, et al. Oral Candida colonization in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility and virulence factors. J Infect Dev Ctries. 2015;9:1350-1359.
59. Sariguzel F, Berk E, Koc AN, Sav H, Demir G. Investigation of the relationship between virulence factors and genotype of Candida spp. isolated from blood cultures. J Infect Dev Ctries. 2015;9:857-864.
60. Favero D, Furlaneto-Maia L, França EJ, Góes HP, Furlaneto MC. Hemolytic factor production by clinical isolates of Candida species. Curr Microbiol. 2014;68:161-166.
61. Seneviratne CJ, Wong SS, Yuen KY, et al. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia. 2011;172:389-395.
62. De Luca C, Guglielminetti M, Ferrario A, Calabr M, Casari E. Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol. 2012;35:459-468.
63. Riceto É, Menezes ReP, Penatti MP, Pedroso RoS. Enzymatic and hemolytic activity in different Candida species. Rev Iberoam Micol. 2015;32:79-82.
64. Abi-Chacra É, Souza LO, Cruz LP, et al. Phenotypical properties associated with virulence from clinical isolates belonging to the Candida parapsilosis complex. FEMS Yeast Res. 2013;13:831-848.